Investment Opportunities

Find Life Science companies you believe can make a difference. 

 

Testing the Waters (EOIs)
Glafabra
One treatment. Years of relief from Fabry disease.

Glafabra Therapeutics is a clinical-stage biotech developing Live-cel cell-based gene therapies for enzyme deficiency disorders such as Fabry, Pompe, and Gaucher disease. Engineered stem cells enable long-lasting enzyme replacement therapy.

Create an account or log in to view or express interest.
$1,000.00 min.
Testing the Waters (EOIs)
PawNoma Bio (Example Issuer)
Veterinary immunotherapy for dogs with cancer

Demo profile only. PawNoma Bio is fictional and is shown for educational purposes only. No securities are being offered or sold, and no investment interest will be accepted, recorded, or transmitted. The Express Interest button is disabled.

Create an account or log in to view or express interest.
$500.00 min.
Testing the Waters (EOIs)
Energesis
Bringing New Energy to the Fight Against Obesity

Energesis is developing oral obesity drug candidates designed to increase energy expenditure by restoring brown fat biology, complementing appetite-focused therapies and advancing next-generation metabolic treatment.

Create an account or log in to view or express interest.
$500.00 min.
 
Investment offerings are highly speculative, illiquid, and subject to risk of loss of the entire amount invested. Certain companies listed on this page may be considering a capital raise and may be “Testing the Waters” under Regulation Crowdfunding. For any company that is Testing the Waters, no money or other consideration is being solicited, and any money or other consideration sent in response will not be accepted. No offer to buy securities may be accepted, and no part of the purchase price may be received, unless and until an offering statement has been filed and investment commitments are accepted only through the BioTech Funding Portal. Submitting an indication of interest via an “Express Interest” button involves no obligation or commitment of any kind.